Sotera Health Company (SHC) Stock Analysis: A Promising 19.38% Potential Upside Captures Investor Attention
Sotera Health Company (SHC) is attracting significant investor interest due to its strong position in the healthcare sector, particularly in sterilization, lab testing, and advisory services. The company, with a $4.86 billion market capitalization, shows financial strength through its revenue growth rate of 9.10% and robust free cash flow, translating to a potential upside of 19.38% based on analyst consensus. Despite technical indicators suggesting it might be oversold, the overwhelmingly positive analyst sentiment and strategic reinvestment focus position SHC as an appealing option for growth-focused investors.
Sotera Health Announces Fourth-Quarter and Full-Year 2025 Earnings Release Date
Sotera Health Company (Nasdaq: SHC) has announced that it will release its financial results for the fourth quarter and full year ended December 31, 2025, before the market opens on Tuesday, February 24, 2026. A conference call will follow at 9:00 a.m. Eastern Time to discuss the results, with a live webcast available on the Company’s Investor Relations website. Sotera Health is a global provider of sterilization, lab testing, and advisory services for the healthcare industry.
Sotera Health Announces Fourth-Quarter and Full-Year 2025 Earnings Release Date
Sotera Health Company (Nasdaq: SHC) announced its plans to release its financial results for the fourth quarter and full year ended December 31, 2025, before the market opens on Tuesday, February 24, 2026. Following the release, a conference call will be held at 9:00 a.m. Eastern Time to discuss operating highlights and financial results. A live webcast and accompanying materials will be available via the Investor Relations section of the Company’s website.
Sotera Health Company (NASDAQ:SHC) Receives Consensus Rating of "Moderate Buy" from Brokerages
Sotera Health Company (NASDAQ:SHC) has received a "Moderate Buy" consensus rating from ten brokerages, with an average 12-month price target of $20.00. Despite recent insider sales totaling 17.38 million shares ($284 million), insiders still retain a significant 47.55% ownership. The stock is currently trading around $17.37, experiencing a slight dip, with a high P/E ratio and debt-to-equity ratio, while institutional investors hold 91.03% of the company's stock.
Sotera Health Adds Independent Director to Board Committees
Sotera Health has expanded its Board of Directors to twelve members by appointing Richard G. Kyle as a new independent Class III director, effective February 4, 2026. Kyle, a former Timken CEO, will serve on the Leadership Development and Compensation Committee and the Nominating and Corporate Governance Committee, aiming to strengthen the company's governance and strategic oversight. Despite mixed financial fundamentals and litigation risks, the company's stock has a "Buy" rating from analysts with a $24.00 price target.
Former Timken CEO joins board of Sotera Health
Sotera Health Co. (Nasdaq: SHC) has appointed Richard G. Kyle, former president and CEO of The Timken Co. (NYSE: TKR), as an independent director. Kyle's extensive experience in global operations, finance, and public company governance is expected to be a significant asset to Sotera Health as it continues to grow. He will serve on the Leadership Development and Compensation, and Nominating and Corporate Governance committees, receiving compensation including an annual cash retainer and restricted stock units.
Sotera Health Appoints Richard Kyle to the Board of Directors
Sotera Health Company has appointed Richard G. Kyle to its Board of Directors as an independent director. Kyle, the former President and CEO of The Timken Company, brings extensive experience in global operations, financial acumen, and public company governance. He will serve on the Leadership Development and Compensation Committee and the Nominating and Corporate Governance Committee, leveraging his background to support Sotera Health's continued growth.
Sotera Health Appoints New Independent Director
Sotera Health has appointed Richard G. Kyle, former CEO of Timken, as a new independent director. Kyle's extensive experience in global operations, financial management, and strategic diversification from his tenure at Timken is expected to enhance Sotera Health's governance and strategic development. He will serve on the Leadership Development and Compensation Committee and the Nominating and Corporate Governance Committee, contributing significantly to the company's continued growth in the healthcare sector.
Former Timken CEO joins Sotera Health board after 2014-24 run
Sotera Health (Nasdaq: SHC) has appointed Richard G. Kyle, former President and CEO of The Timken Company, to its Board of Directors effective February 5, 2026. Kyle will join the Leadership Development and Compensation and Nominating and Corporate Governance committees. His appointment leverages his extensive experience in global operations, financial transformation, and public company governance.
Sotera Health Appoints Richard Kyle to the Board of Directors
Sotera Health Company (Nasdaq: SHC) has appointed Richard G. Kyle as a new independent director to its Board of Directors. Mr. Kyle, former President and CEO of The Timken Company, brings extensive experience in global operations, financial acumen, and public company governance. He will serve on the Leadership Development and Compensation Committee and the Nominating and Corporate Governance Committee.
Sotera Health Appoints Richard Kyle to the Board of Directors
Sotera Health Company has appointed Richard G. Kyle to its Board of Directors as an independent director. Mr. Kyle, previously CEO of The Timken Company, brings extensive experience in global operations, financial acumen, and public company governance. He will serve on the Leadership Development and Compensation Committee and the Nominating and Corporate Governance Committee.
Sotera Health Company's (NASDAQ:SHC) institutional investors lost 3.1% last week but have benefitted from longer-term gains
Institutional investors in Sotera Health Company (NASDAQ:SHC) experienced a 3.1% loss last week, despite having gained from 31% one-year returns. Institutions hold a significant 50% stake, giving them substantial influence over the company's share price. This analysis highlights the different ownership types, including institutional investors, hedge funds, insiders, the general public, and private equity firms, to understand their collective impact on Sotera Health.
Sotera Health Company's (NASDAQ:SHC) institutional investors lost 3.1% last week but have benefitted from longer-term gains
Institutional investors in Sotera Health Company (NASDAQ:SHC) experienced a 3.1% loss last week but overall have seen gains over a longer term, with a 31% return over the past year. Institutions hold a significant 50% stake in the company, suggesting considerable influence over its share price. While hedge funds and private equity firms also have notable holdings, company insiders collectively own shares valued at approximately US$112 million, indicating meaningful alignment with the company's performance.
Sotera Health Company's (NASDAQ:SHC) institutional investors lost 3.1% last week but have benefitted from longer-term gains
Institutional investors in Sotera Health Company experienced a 3.1% loss last week, despite having benefited from 31% gains over the past year. Institutions hold a significant 50% stake in the company, giving them considerable influence. Recent insider selling has also been noted.
Sotera Health announces secondary offering of common stock
Sotera Health has announced a secondary offering of 18,000,000 shares of its common stock by certain selling stockholders. The company will not sell any shares in this offering and will not receive any proceeds from the sale. The offering is subject to market and other conditions.
Sotera Health Company (SHC): Buy, Sell, or Hold Post Q3 Earnings?
This article analyzes Sotera Health Company (SHC) after its Q3 earnings, noting a significant stock price jump. Despite recent gains, the author expresses caution due to the company's relatively small size in a scale-driven industry, slim projected revenue growth, and a dropping free cash flow margin. The analysis concludes that SHC does not present an exciting investment opportunity at its current valuation.
Sotera Health Company (NASDAQ:SHC) Given Average Recommendation of "Moderate Buy" by Brokerages
Sotera Health Company (NASDAQ:SHC) has received a consensus "Moderate Buy" rating from brokerages, with an average 12-month price target of $20. Despite recent significant insider selling, including shares from GTCR and the CEO totaling over $470 million, insiders still retain 47.55% ownership. The company reported strong Q3 earnings, beating EPS and revenue estimates, and provided an optimistic FY2025 guidance.
Does Sotera Health’s 2025 Outlook And Capital Plan Reinforce The Bull Case For SHC?
Sotera Health's 2025 outlook forecasts revenue exceeding US$1.16 billion, indicating over 5.5% year-over-year growth and extending a 20-year streak of increases. The company plans to prioritize organic expansion through capital, alongside selective M&A, debt reduction, and share repurchases. This strategy supports the existing investment narrative focusing on capacity expansion and deleveraging, despite ongoing risks related to ethylene oxide (EO) regulation and litigation costs.
Sotera Health Company (SHC) Stock Analysis: Strong Buy Ratings and 7.68% Potential Upside
Sotera Health Company (SHC) has garnered strong buy ratings from analysts, indicating a potential upside of 7.68%. The company, a key healthcare provider in sterilization, lab testing, and advisory services, shows robust financial health with a $5.39 billion market capitalization and a 9.10% revenue growth rate. Technical indicators also suggest a bullish momentum, positioning SHC as an attractive investment in the growing healthcare sector.
Sotera Health sees FY25 revenue over $1.16B, consensus $1.16B
Sotera Health (SHC) anticipates its fiscal year 2025 revenue to exceed $1.16 billion, aligning with the current consensus. This projection represents a minimum 5.5% year-over-year growth, or 5.0% on a constant-currency basis, extending a two-decade streak of revenue increases. The company's CEO, Michael B. Petras, Jr., highlighted the durability of their business model and the strength of their financial profile during the 44th Annual J.P. Morgan Healthcare Conference, with full-year results and 2026 outlook expected on February 24, 2026.
Sotera Health to Showcase Continued Revenue Growth and Strategic Value Creation at 44th Annual J.P. Morgan Healthcare Conference
Sotera Health is presenting at the 44th Annual J.P. Morgan Healthcare Conference, where management will provide a business update. The company expects to surpass $1.16 billion in revenue for 2025, marking over two decades of year-over-year growth, and plans to release its full-year results and 2026 outlook on February 24, 2026. A webcast of the presentation is available on the Company’s Investor Relations website.
Wells Fargo Initiates Sotera Health Company(SHC.US) With Buy Rating, Announces Target Price $24
Wells Fargo analyst Ryan Halsted has initiated coverage on Sotera Health Company (SHC.US) with a 'Buy' rating and set a target price of $24. The analyst has a track record of 50.0% success rate and an average return of 6.4% over the past year, according to TipRanks data. This information is intended for informational purposes and does not constitute investment advice.
Sotera Health to Present at the 44th Annual J.P. Morgan Healthcare Conference
Sotera Health Company announced it will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. Management will deliver a presentation at 1:30 p.m. Eastern Time, with a live webcast available on the Company's Investor Relations website. A replay of the presentation will also be archived on their website for 48 hours following the event.
Sotera Health Stock Pre-Market (+5.2%): Positive Commentary Ahead of J.P. Morgan Conference
Sotera Health's stock is up 5.2% in pre-market trading following positive commentary. This surge comes ahead of the company's participation in the J.P. Morgan Conference. The article suggests investor interest based on recent developments.
RBC Capital initiates Sotera Health stock with Outperform rating By Investing.com
RBC Capital has initiated coverage on Sotera Health (NASDAQ:SHC) with an Outperform rating and a $24.00 price target, citing the company's strong fundamentals, high-margin profile, and defensible sterilization capacity in a growing medical device market. This assessment is supported by InvestingPro data and aligns with recent positive financial results and other analyst initiations. The firm also notes a favorable risk-reward balance despite ongoing legal risks related to ethylene oxide litigation.
Piper Sandler upgrades Sotera Health stock rating to Overweight on improved demand
Piper Sandler has upgraded Sotera Health (NASDAQ:SHC) from Neutral to Overweight, increasing its price target to $24.00 from $17.00 due to improved end-market demand for its Sterigenics franchise and stronger company-wide execution. The firm noted consistent profit and loss beats, balance sheet deleveraging, and improved cash flow. This upgrade, alongside positive reports from RBC Capital, William Blair, and Jefferies, reflects growing analyst confidence in Sotera Health's market position and financial performance.
RBC Capital initiates Sotera Health stock with Outperform rating
RBC Capital has initiated coverage on Sotera Health (NASDAQ:SHC) with an Outperform rating and a $24.00 price target, citing strong fundamentals, high-margin profiles, and a defensible market position in healthcare sterilization services. This positive outlook is supported by recent strong financial results, analyst upgrades, and the company's strategic positioning, despite ongoing legal risks. Sotera Health's market capitalization stands at $5.34 billion, with analysts maintaining a strong Buy consensus.
Is Sotera Health Company (NASDAQ:SHC) Potentially Undervalued?
Sotera Health Company (NASDAQ:SHC) appears to be undervalued based on its intrinsic value of $25.71, which is higher than its current market price. The company's future outlook is optimistic, with earnings expected to double in the next few years, suggesting strong cash flow and a higher share value. This presents a potential buying opportunity for investors, though other factors like capital structure and management track record should also be considered.
RBC Capital initiates Sotera Health stock with Outperform rating By Investing.com
RBC Capital has initiated coverage on Sotera Health (NASDAQ:SHC) with an Outperform rating and a $24.00 price target, citing the company's healthy fundamentals, high-margin profile, and a defensible market position in healthcare sterilization services. This positive outlook is supported by Sotera's strong gross profit margins and consistent financial performance, including a recent beat on Q3 2025 earnings and revenue. The firm also weighed the favorable risk-reward balance despite ongoing ethylene oxide litigation.
RBC Capital initiates Sotera Health stock with Outperform rating By Investing.com
RBC Capital has initiated coverage on Sotera Health (NASDAQ:SHC) with an Outperform rating and a price target of $24.00, citing the healthcare sterilization company's strong fundamentals, high margin profiles, and defensible market position. The firm expects sustainable high-single-digit growth and modest margin expansion, despite ongoing legal risks. This positive analyst sentiment is supported by the company's recent strong Q3 2025 financial results, which exceeded analysts' expectations.
Sotera Health Director Warburg Pincus Sells 9.7 Million Shares for $158.7 Million
Warburg Pincus, a director of Sotera Health, indirectly sold 9.7 million shares of the company for $158.7 million on December 3, 2025. This transaction reduced Warburg Pincus's indirect stake by 22.18%, though they still hold over 34 million shares. The sale occurred after a strong year for Sotera Health's stock, benefiting from favorable market conditions.
Sotera Health to Present at the 44th Annual J.P. Morgan Healthcare Conference
Sotera Health Company announced it will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 1:30 p.m. Eastern Time. Company management will participate in investor meetings, and a live webcast of the presentation will be available on their Investor Relations website. Sotera Health is a global provider of sterilization, lab testing, and advisory services for the healthcare industry through its Sterigenics, Nordion, and Nelson Labs businesses.
Sotera Health to Present at the 44th Annual J.P. Morgan Healthcare Conference
Sotera Health Company (NASDAQ: SHC) announced that its management will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 1:30 p.m. Eastern Time. A live webcast of the presentation and accompanying materials will be available on the Investor Relations section of the Company’s website, with a replay accessible within 48 hours. Sotera Health is a global provider of sterilization solutions, lab testing, and advisory services for the healthcare industry.
Sotera Health to Present at the 44th Annual J.P. Morgan Healthcare Conference
Sotera Health Company announced its management will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 1:30 p.m. Eastern Time. A live webcast and replay of the presentation will be available on the Investor Relations section of the company's website. Sotera Health is a global provider of sterilization solutions, lab testing, and advisory services for the healthcare industry.
Sotera Health to Present at the 44th Annual J.P. Morgan Healthcare Conference
Sotera Health Company (NASDAQ: SHC) announced its management will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 1:30 p.m. ET. A live webcast and replay of the presentation will be available on the Investor Relations section of the Company’s website. Sotera Health is a global provider of sterilization, lab testing, and advisory services, operating through Sterigenics®, Nordion®, and Nelson Labs®.
How Sotera Health Company (SHC) Affects Rotational Strategy Timing
This article analyzes Sotera Health Company (SHC) using AI models to provide institutional trading strategies for different risk profiles. It identifies strong sentiment across all time horizons, supporting an overweight bias for SHC, and details specific entry, target, and stop-loss points for position, momentum, and risk-hedging strategies. The analysis highlights an exceptional risk-reward short setup and provides multi-timeframe signal analysis with support and resistance levels.
Sotera Health Co stock hits 52-week high at 17.83 USD
Sotera Health Co (SHC) recently hit a 52-week high of $17.83 per share, reflecting a 51.55% price return over six months and a 30.01% increase over the past year. The company's financial health is rated "GOOD" by InvestingPro, with analysts setting price targets between $16 and $21. This performance follows strong Q3 2025 financial results, including an adjusted EPS of $0.26 and revenue of $311 million, exceeding analysts' expectations.
Sotera Health Co stock hits 52-week high at $17.79 By Investing.com
Sotera Health Co (SHC) stock has reached a new 52-week high of $17.79, reflecting a 28.49% increase over the past year and a 54.89% return in six months. This surge is supported by strong investor confidence, positive market conditions, and a "GOOD" financial health score, with analysts anticipating net income growth. The company also recently reported strong Q3 2025 financial results, exceeding analyst expectations, and announced a secondary offering.
Why Sotera Health (SHC) Is Up 5.3% After Margin-Beating Quarter Signals Efficiency Gains
Sotera Health (SHC) saw its stock rise by 5.3% after reporting a strong quarter with revenues up 9.1% year-on-year, beating analyst estimates, and achieving double-digit adjusted EBITDA growth alongside 150 basis points of margin expansion. These results highlight significant efficiency gains in its sterilization and lab testing operations. Despite these improvements, the company still faces risks related to ongoing ethylene oxide (EO) regulation and legal exposure, which management is addressing through elevated capital expenditure.
Sotera Health Co stock hits 52-week high at $17.79
Sotera Health Co's stock reached a new 52-week high of $17.79, reflecting strong investor confidence and positive market conditions. The company has seen significant stock price increases over the past year and six months, with analysts expecting net income growth. Recent news also highlights strong Q3 2025 financial results and positive analyst ratings.
Sotera Health Company (NASDAQ:SHC) Given Average Rating of "Moderate Buy" by Brokerages
Sotera Health Company (NASDAQ:SHC) has received an average "Moderate Buy" rating from seven brokerages, with a mean 12-month price target of $17.80. This sentiment comes despite significant insider selling totaling approximately $471.8 million in the last three months, though insiders still hold a substantial 55.12% of the stock. The company recently surpassed Q3 earnings expectations and provided optimistic FY2025 guidance.
Q3 Research Tools & Consumables Earnings: Sotera Health Company (NASDAQ:SHC) Earns Top Marks
Sotera Health Company (SHC) led the research tools & consumables sector in Q3 earnings, reporting strong revenue growth and exceeding analyst expectations. The company, crucial for patient safety in medical devices and pharmaceuticals, posted a 9.1% year-on-year revenue increase to $311.3 million. While Agilent (A), Danaher (DHR), and Thermo Fisher (TMO) also had strong quarters, Avantor (AVTR) struggled with declining revenues.
William Blair Initiates Sotera Health Company(SHC.US) With Buy Rating
William Blair analyst Max Smock has initiated coverage on Sotera Health Company (SHC.US) with a 'buy' rating. Smock has a 68.2% success rate and a 6.7% average return over the past year, according to TipRanks data. The rating reflects a positive outlook on Sotera Health Company's stock performance.
Sotera Health Looks Undervalued, Analyst Says - Sotera Health (NASDAQ:SHC)
William Blair initiated coverage on Sotera Health (NYSE: SHC) with an Outperform rating, noting the company appears undervalued despite its strong market position and best-in-class margins. The analyst believes easing ethylene oxide litigation risks and improving free cash flow will lead to a re-rating of the stock, predicting approximately 45% upside over the next two years. Sotera Health's integrated sterilization platform and sticky customer base are highlighted as key strengths.
Sotera Health, Warburg Pincus, and GTCR in $470 Million Secondary Stock Offering
Cleary Gottlieb represented Sotera Health, Warburg Pincus, and GTCR in a $470 million secondary public offering of 30 million shares of common stock. The offering, which priced on November 6, 2025, involves only selling shareholders, with Sotera Health not selling any shares or receiving proceeds. Goldman Sachs & Co. LLC is acting as the underwriter for this transaction.
Sotera Health announces secondary offering of common stock
Sotera Health has announced a secondary offering of common stock. Details regarding the number of shares and pricing were not immediately available, and the offering is being conducted by existing shareholders.
Michael Jr. Petras Sells 434,104 Shares of Sotera Health (NASDAQ:SHC) Stock
Michael Jr. Petras, CEO of Sotera Health (NASDAQ:SHC), sold 434,104 shares of the company's stock on December 8th at an average price of $16.45, totaling over $7.1 million. This transaction occurred as the company reported strong earnings, exceeding analyst expectations, and issued positive FY2025 guidance. Sotera Health's stock is currently trading near its 52-week high with a "Moderate Buy" consensus rating from analysts.
Sotera Health Company(SHC.US) Officer Sells US$12.34 Million in Common Stock
An officer of Sotera Health Company (SHC.US), Petras Michael B. Jr., sold 750,000 shares of common stock on December 8, 2025, for a total of $12.34 million. The sale was executed at an average price of $16.45 per share. This transaction falls under federal securities laws requiring insiders to report changes in their securities holdings.
Sotera Health (SHC) chairman Petras sells shares worth $12.3m
Michael B. Petras Jr., Chairman and CEO of Sotera Health Co (NASDAQ:SHC), sold 749,199 shares of common stock for approximately $12.3 million on December 8, 2025. These sales were executed at $16.45 per share, slightly below the current trading price. The company has a market capitalization of $4.75 billion and its shares have surged 35.85% over the past six months, currently trading near their 52-week high.
Sotera Health (SHC) chairman Petras sells shares worth $12.3m
Sotera Health (NASDAQ:SHC) Chairman and CEO Michael B. Petras Jr. sold 749,199 shares of common stock for approximately $12.3 million on December 8, 2025. These sales were executed at $16.45 per share, with Petras directly owning 552,790 shares afterward. The company recently reported strong Q3 2025 earnings and announced a secondary offering of 30 million shares, while Jefferies reiterated a "Buy" rating.
